American Society of Hirudotherapy

[Hirudin--comeback of Hirudo medicinalis]

Research article published in Duodecim; laaketieteellinen aikakauskirja (1992)

Last Updated: March 18, 2026Reviewed by: ASH Editorial Board
Research article — evidence reviewArticle reference
Drug DevelopmentGenomics & ProteomicsLassila R · Duodecim; laaketieteellinen aikakauskirja, 1992

Summary

[Hirudin--comeback of Hirudo medicinalis].

Why This Matters for Hirudotherapy

Relevant to the development and clinical application of leech-derived pharmaceutical compounds.

Citation

[Hirudin--comeback of Hirudo medicinalis].

Lassila R · Duodecim; laaketieteellinen aikakauskirja, 1992

DOI

Added to ASH library: March 18, 2026 · Site last updated: March 18, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.

[Hirudin--comeback of Hirudo medicinalis] | ASH